Financière de Tubize SA Efectivo por acción
¿Qué es el Efectivo por acción de Financière de Tubize SA?
El Efectivo por acción de Financière de Tubize SA es 0.01
¿Cuál es la definición de Efectivo por acción?
El efectivo por acción es el efectivo disponible de una compañía dividido por las acciones de la compañía en circulación.
Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.
When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.
Efectivo por acción de compañías en Sector Health Care en EURONEXT en comparadas con Financière de Tubize SA
¿Qué hace Financière de Tubize SA?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Empresas con efectivo por acción similar a Financière de Tubize SA
- Ling Yui tiene Efectivo por acción de 0.01
- Great Harvest Maeta tiene Efectivo por acción de 0.01
- K W Nelson Interior Design and Contracting tiene Efectivo por acción de 0.01
- WMCH Global Investment tiene Efectivo por acción de 0.01
- TNG tiene Efectivo por acción de 0.01
- MKB Nedsense NV tiene Efectivo por acción de 0.01
- Financière de Tubize SA tiene Efectivo por acción de 0.01
- International Tower Hill Mines Ltd tiene Efectivo por acción de 0.01
- Sienna Cancer Diagnostics tiene Efectivo por acción de 0.01
- FinTech Acquisition III tiene Efectivo por acción de 0.01
- Jackson Acquisition tiene Efectivo por acción de 0.01
- US Copper tiene Efectivo por acción de 0.01
- Argo Gold tiene Efectivo por acción de 0.01